After 4 long years of await, Revlimid as maintenance therapy is nearing reimbursement listing in Korea.

According to industry sources, the agenda of reimbursing Revlimid as maintenance therapy that has passed deliberations by the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee in June will be deliberated at this year’s final Health Insurance Policy Deliberation Committee meeting.

If this last procedure progresses and is completed without issues, the drug’s reimbursement is expected to be expanded from 2023.

The agenda of using Revlimid as maintenance therapy had undergone various twists and turns in Korea. Since 2019, BMS Korea h